For regular monitoring of hearing status, FGF23 and D-serine levels are needed to assess the risk of hearing impairment in patients with chronic renal failure in order to prevent and detect hearing impairment in a timely manner and to reduce the increased disability, decreased quality of life, and increased disease burden in patients with chronic renal failure due to hearing loss. This evidence concerns the gene FGF23 and Hearing impairment.